Coibamide A kills cancer cells through inhibiting autophagy

Biochem Biophys Res Commun. 2021 Apr 2:547:52-58. doi: 10.1016/j.bbrc.2021.01.112. Epub 2021 Feb 13.

Abstract

Natural products are useful tools for biological mechanism research and drug discovery. Due to the excellent tumor cell growth inhibitory profile and sub-nanomolar potency, Coibamide A (CA), an N-methyl-stabilized depsipeptide isolated from marine cyanobacterium, has been considered as a promising lead compound for cancer treatment. However, the molecular anti-cancer mechanism of the action of CA remains unclear. Here, we showed that CA treatment induced caspase-independent cell death in breast cancer cells. CA treatment also led to severe lysosome defects, which was ascribed to the impaired glycosylation of lysosome membrane protein LAMP1 and LAMP2. As a consequence, the autophagosome-lysosome fusion was blocked upon CA treatment. In addition, we presented evidence that this autophagy defect partially contributed to the CA treatment-induced tumor cell death. Together, our work uncovers a novel mechanism underlying the anti-cancer action of CA, which will promote its further application for cancer therapy.

Keywords: Autophagy mediated cell death; Coibamide a; LAMP protein Glycosylation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Autophagosomes / drug effects*
  • Autophagosomes / metabolism
  • Autophagy / drug effects
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Depsipeptides / pharmacology*
  • Female
  • Humans
  • Lysosomes / drug effects*
  • Lysosomes / metabolism
  • Signal Transduction

Substances

  • Antineoplastic Agents
  • Depsipeptides
  • coibamide A